Loading
A phase 1/2 trial of IN10018 in ovarian cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer is a phase 1/2 interventional study registered as NCT05551507 by InxMed (Shanghai) Co., Ltd., with 150 participants planned, started 2020-07-27 and due to reach its primary completion in 2026-05-31. Interventions recorded: IN10018 in combination with PLD. Conditions listed: Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares InxMed, IN10018, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/